Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Cell Host Microbe. 2021 Jan 13;29(1):13-22. doi: 10.1016/j.chom.2020.12.011.
More than 390 million human dengue virus (DENV) infections occur each year, worldwide. Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for human clinical use, although vaccine performance against the four DENV serotypes is highly variable. Other dengue vaccines in advanced clinical testing also demonstrate variability in efficacy. In this review, we outline the benefits and challenges of developing a safe, effective, and balanced DENV vaccine that can provide uniform protection against all four serotypes. Even though T cell biology plays an important role in establishing protective immunity, this review focuses on B cell responses. We discuss the leading dengue vaccine candidates and review the specificity of antibody responses and the known immune correlates of protection against DENV infection. A better understanding of immune correlates of protection against DENV infection will inform the development of a vaccine that can provide long-term, uniform protection.
每年，全球有超过 3.9 亿人感染人类登革热病毒 (DENV)。赛诺菲巴斯德的一种活病毒四价疫苗——登革热疫苗（Dengvaxia）最近已获准在临床上使用，尽管该疫苗对四种 DENV 血清型的疗效差异很大。其他处于临床测试后期的登革热疫苗也显示出疗效的差异。在这篇综述中，我们概述了开发一种安全、有效和平衡的 DENV 疫苗的好处和挑战，这种疫苗可以为所有四种血清型提供一致的保护。尽管 T 细胞生物学在建立保护性免疫方面发挥着重要作用，但本综述侧重于 B 细胞反应。我们讨论了领先的登革热疫苗候选物，并回顾了抗体反应的特异性以及针对 DENV 感染的已知免疫保护相关因素。更好地了解针对 DENV 感染的免疫保护相关因素将为开发能够提供长期、一致保护的疫苗提供信息。
